Benefits

L2D provides multiple benefits to both its clients and their investors.

Outsourcing early stage therapeutic development management to L2D permits a company’s investors and shareholders to minimise their investment risk. Our experienced team ensures that projects are initiated rapidly and completed according to a carefully optimised timeline. Costs are minimised, not only due to our operational experience, but also due to our knowledge of the CRO/CMO market and our contract negotiation skills.

Outsourcing a company's early stage development programme to L2D also provides independent project validation that will generate added value for any third party wishing to acquire the therapeutic agent or programme at a later date.

Select L2D - LeadsToDevelopment - for your drug development outsourcing requirements - we deliver non-clinical development expertise to clients who wish to outsource the management of their preclinical development plan, non-clinical studies and preclinical evaluation activities.